ClinicalTrials.gg
TerminatedNCT01876251Updated Mar 15, 2019Results posted

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

A Phase 1 interventional study of PF-03084014 and PF-03084014 in Breast Cancer Metastatic, sponsored by Pfizer. Terminated at 16 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.

Enrollment
89th of 121
30 · median 75
Started
2013
with 9 others
Phase 1
37 of 182
2 open now
Registered
70th of 182
by date

Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 89th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2013, is one of 37 in phase 1, and was the 70th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

03

Conditions studied

  • Breast Cancer Metastatic

Browse trials for

Keywords

  • Breast cancer metastatic
  • docetaxel
  • PF-03084014
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of breast cancer with evidence of a) or b) locally recurrent/advanced disease.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    PF-03084014 plus docetaxel

    PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2

    Drug: PF-03084014 · Drug: Docetaxel

Interventions

  • Tablet, 10 mg, twice a day

  • Tablet, 50 mg, twice a day

  • Tablet, 100 mg, twice a day

  • Solution for IV infusion 75 mg/m\^2, every 3 weeks

    Also known as: Taxotere

  • Solution for IV infusion 100 mg/m\^2, every 3 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1

    Any DLT event in Cycle 1: Grade 4 neutropenia lasting more than (\>)7 days; febrile neutropenia (Grade more than or equal to \[\>=\] 3 and body temperature \>=38.5 degrees Celsius); Grade \>=3 neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia without bleeding; Grade \>=3 toxicities (except those that had not been maximally treated); Grade 3 prolongation of time from electrocardiogram (ECG) Q wave to the end of the T wave corresponding to electrical systole (QT) corrected for heart rate (QTc) which persisted after correction of reversible causes; delay of 2 weeks in receiving next scheduled cycle due to persisting treatment-related toxicities; and failure to deliver at least 80% of planned dose during first cycle due to treatment-related toxicities.

    Time frame: Cycle 1 Days 1-21

  2. Progression-free Survival (PFS) at 6 Months - Expansion Cohort

    The period from study entry until disease progression, death or date of last contact. Assessment of response was made using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Baseline till 6 months post-dose

Secondary outcomes

  1. Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs (TEAEs) are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Causality assessment was made by the investigator. Grading was per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death related to AE.

    Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)

  2. Number of Participants With Laboratory Abnormalities

    Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick).

    Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)

  3. Percentage of Participants With Objective Response (OR)

    OR was based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 6 weeks from Cycle 2 onwards up to 26 months

  4. Area Under the Concentration-time Curve (AUC) From Time 0 to Time of Last Measured Concentration (AUClast) of PF-03084014 in Dose-finding Cohort

    Serum PF-03084014 pharmacokinetic (PK) parameters were calculated following twice daily (BID) doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1).

    Time frame: Cycle (C) 1 Days (D) 1, 2, 8, and 21; Day 1 of subsequent cycles and at EOT (max reached: Cycle 12)

  5. AUClast and AUC From Time 0 Extrapolated to Infinite Time (AUCinf) of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  6. Maximum Serum or Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of PF-03084014 in Dose-finding Cohort

    Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  7. Cmax of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  8. Time to Cmax (Tmax) of PF-03084014 in Dose-finding Cohort

    Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  9. Tmax of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  10. Systemic Clearance (CL) of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  11. Terminal Half-life (t1/2) of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  12. Volume of Distribution (Vss) of Docetaxel in Dose-finding Cohort

    Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

    Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)

  13. AUClast of PF-03084014 in the Expansion Cohort

    Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)

  14. Cmax of PF-03084014 in the Expansion Cohort

    Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)

  15. Tmax of PF-03084014 in the Expansion Cohort

    Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)

  16. Ctrough of PF-03084014 in the Expansion Cohort

    Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)

  17. Duration of Response (DR)

    Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

    Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)

  18. Number of Participants With QTc Values Meeting Categorical Summarization Criteria

    Criteria for categorical summarization of the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT) corrected for heart rate (QTc) using Bazett's correction (QTcB) or Fridericia's correction (QTcF) included: maximum QTcB or QTcF less than or equal to (\<=) 450 milliseconds (msec), 450 to \<=480 msec, 480 to \<=500 msec, more than (\>) 500 msec; maximum QTcB or QTcF changes (increases/decreases) from baseline (BL) less than (\<) 30 msec, 30 to \<60 msec, more than or equal to (\>=) 60 msec.

    Time frame: Screening, C1D1, C1D21, Day 1 of subsequent cycles, and EOT (maximum reached: C12)

  19. Percentage Change From Baseline in Notch 1 to 4 Ribonucleic Acid (RNA) in Blood

    As PF-03084014 acts on the Notch pathway as an inhibitor, it is of interest to investigate its effects, if any, on the Notch family of receptors, mainly Notch 1-4.

    Time frame: C1D1, C1D2, C1D8, C1D21 and EOT (maximum reached: C12)

07

Results

Posted Mar 15, 2019

Participant flow

Participant flow — Overall Study
MilestonePF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Started15311
Completed000
Not completed15311
Withdrew: Clinical progression100
Withdrew: Death201
Withdrew: Participant started new treatment101
Withdrew: Participant refused further follow-up001
Withdrew: Study terminated100
Withdrew: Objective progression or relapse1038

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1

Any DLT event in Cycle 1: Grade 4 neutropenia lasting more than (\>)7 days; febrile neutropenia (Grade more than or equal to \[\>=\] 3 and body temperature \>=38.5 degrees Celsius); Grade \>=3 neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia without bleeding; Grade \>=3 toxicities (except those that had not been maximally treated); Grade 3 prolongation of time from electrocardiogram (ECG) Q wave to the end of the T wave corresponding to electrical systole (QT) corrected for heart rate (QTc) which persisted after correction of reversible causes; delay of 2 weeks in receiving next scheduled cycle due to persisting treatment-related toxicities; and failure to deliver at least 80% of planned dose during first cycle due to treatment-related toxicities.

Time frame:
Cycle 1 Days 1-21
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1
participantsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1114
PrimaryProgression-free Survival (PFS) at 6 Months - Expansion Cohort

The period from study entry until disease progression, death or date of last contact. Assessment of response was made using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Time frame:
Baseline till 6 months post-dose
Reported as:
Median · months
Progression-free Survival (PFS) at 6 Months - Expansion Cohort
monthsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2
Progression-free Survival (PFS) at 6 Months - Expansion Cohort4.1 (1.3 to 8.1)
SecondaryNumber of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs (TEAEs) are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Causality assessment was made by the investigator. Grading was per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death related to AE.

Time frame:
Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Reported as:
Number · participants
Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs
participantsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
All causality TEAEs15311
Treatment-related (TR) TEAEs15311
All causality SAEs436
TR SAEs336
Grade 3 or 4 TEAEs, all causality15311
Grade 3 or 4 TEAEs, TR15311
Grade 5 TEAEs, all causality101
Grade 5 TEAEs, TR001
Permanent withdrawal due to all causality TEAE(s)116
Permanent withdrawal due to TR TEAE(s)114
SecondaryNumber of Participants With Laboratory Abnormalities

Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick).

Time frame:
Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities
participantsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Number of Participants With Laboratory Abnormalities15311
SecondaryPercentage of Participants With Objective Response (OR)

OR was based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 6 weeks from Cycle 2 onwards up to 26 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Percentage of Participants With Objective Response (OR)13.3 (1.7 to 40.5)0 (0.0 to 70.8)18.2 (2.3 to 51.8)
SecondaryArea Under the Concentration-time Curve (AUC) From Time 0 to Time of Last Measured Concentration (AUClast) of PF-03084014 in Dose-finding Cohort

Serum PF-03084014 pharmacokinetic (PK) parameters were calculated following twice daily (BID) doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1).

Time frame:
Cycle (C) 1 Days (D) 1, 2, 8, and 21; Day 1 of subsequent cycles and at EOT (max reached: Cycle 12)
Reported as:
Geometric mean · nanogram (ng)*hour (hr)/milliliter (mL)
Area Under the Concentration-time Curve (AUC) From Time 0 to Time of Last Measured Concentration (AUClast) of PF-03084014 in Dose-finding Cohort
nanogram (ng)*hour (hr)/milliliter (mL)PF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
C1D21779 ± 631380 ± 571839 ± 32
C1D214119 ± 393234 ± 215575 ± 59
C2D11983 ± 53NA ± NA2652 ± 28
SecondaryAUClast and AUC From Time 0 Extrapolated to Infinite Time (AUCinf) of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · nanogram (ng)*hour (hr)/milliliter (mL)
AUClast and AUC From Time 0 Extrapolated to Infinite Time (AUCinf) of Docetaxel in Dose-finding Cohort
nanogram (ng)*hour (hr)/milliliter (mL)PF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
AUClast, C1D13535 ± 1134082 ± 362121 ± 49
AUClast, C2D12377 ± 29NA ± NA2136 ± 47
AUCinf, C1D1NA ± NANA ± NA2509 ± 63
AUCinf, C2D12530 ± 30NA ± NA2929 ± 3
SecondaryMaximum Serum or Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of PF-03084014 in Dose-finding Cohort

Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · ng/mL
Maximum Serum or Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of PF-03084014 in Dose-finding Cohort
ng/mLPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Cmax, C1D2884.8 ± 56744.2 ± 51896.6 ± 40
Cmax, C1D211053 ± 51677.5 ± 371501 ± 44
Ctrough, C1D21214.7 ± 39170.8 ± 36306.1 ± 72
Cmax, C2D1885.7 ± 95NA ± NA1100 ± 21
Ctrough, C2D1186.1 ± 42NA ± NA226.4 ± 65
SecondaryCmax of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · ng/mL
Cmax of Docetaxel in Dose-finding Cohort
ng/mLPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Cmax, C1D13711 ± 1833447 ± 572103 ± 68
Cmax, C2D12606 ± 29NA ± NA1965 ± 35
SecondaryTime to Cmax (Tmax) of PF-03084014 in Dose-finding Cohort

Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Median · hr
Time to Cmax (Tmax) of PF-03084014 in Dose-finding Cohort
hrPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Tmax, C1D21.00 (0.500 to 1.03)1.02 (1.00 to 4.00)1.00 (0.500 to 1.03)
Tmax, C1D210.533 (0.417 to 1.00)1.00 (0.500 to 4.03)0.767 (0.500 to 2.00)
Tmax, C2D10.883 (0.000 to 1.00)1.03 (1.00 to 1.05)0.992 (0.500 to 1.02)
SecondaryTmax of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Median · hr
Tmax of Docetaxel in Dose-finding Cohort
hrPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Tmax, C1D11.00 (0.500 to 1.05)0.917 (0.500 to 1.00)0.983 (0.500 to 1.05)
Tmax, C2D11.00 (0.517 to 1.03)0.767 (0.533 to 1.00)1.00 (0.500 to 1.50)
SecondarySystemic Clearance (CL) of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · liter (L)/hr
Systemic Clearance (CL) of Docetaxel in Dose-finding Cohort
liter (L)/hrPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
CL, C1D1NA ± NANA ± NA55.51 ± 70
CL, C2D151.97 ± 23NA ± NA45.40 ± 5
SecondaryTerminal Half-life (t1/2) of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Mean · hr
Terminal Half-life (t1/2) of Docetaxel in Dose-finding Cohort
hrPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
t1/2, C1D118.35 ± NA6.555 ± NA7.624 ± 5.368
t1/2, C2D15.500 ± 7.259NA ± NA14.27 ± 3.420
SecondaryVolume of Distribution (Vss) of Docetaxel in Dose-finding Cohort

Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)

Time frame:
C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · L
Volume of Distribution (Vss) of Docetaxel in Dose-finding Cohort
LPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Vss, C1D1NA ± NANA ± NA97.34 ± 73
Vss, C2D157.37 ± 127NA ± NA231.5 ± 25
SecondaryAUClast of PF-03084014 in the Expansion Cohort
Time frame:
C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · ng*hr/mL
AUClast of PF-03084014 in the Expansion Cohort
ng*hr/mLPF-03084014 100 mg BID + Docetaxel 75 mg/m^2
AUClast, C1D11098 ± 47
AUClast, C1D211955 ± 16
SecondaryCmax of PF-03084014 in the Expansion Cohort
Time frame:
C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · ng/mL
Cmax of PF-03084014 in the Expansion Cohort
ng/mLPF-03084014 100 mg BID + Docetaxel 75 mg/m^2
Cmax, C1D1496.7 ± 70
Cmax, C1D21982.1 ± 20
SecondaryTmax of PF-03084014 in the Expansion Cohort
Time frame:
C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Median · hr
Tmax of PF-03084014 in the Expansion Cohort
hrPF-03084014 100 mg BID + Docetaxel 75 mg/m^2
Tmax, C1D10.983 (0.500 to 1.00)
Tmax, C1D211.00 (0.483 to 1.00)
SecondaryCtrough of PF-03084014 in the Expansion Cohort
Time frame:
C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Reported as:
Geometric mean · ng/mL
Ctrough of PF-03084014 in the Expansion Cohort
ng/mLPF-03084014 100 mg BID + Docetaxel 75 mg/m^2
Ctrough of PF-03084014 in the Expansion Cohort89.22 ± 51
SecondaryDuration of Response (DR)

Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

Time frame:
Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Reported as:
Number · months
Duration of Response (DR)
monthsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Duration of Response (DR)NANA
SecondaryNumber of Participants With QTc Values Meeting Categorical Summarization Criteria

Criteria for categorical summarization of the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT) corrected for heart rate (QTc) using Bazett's correction (QTcB) or Fridericia's correction (QTcF) included: maximum QTcB or QTcF less than or equal to (\<=) 450 milliseconds (msec), 450 to \<=480 msec, 480 to \<=500 msec, more than (\>) 500 msec; maximum QTcB or QTcF changes (increases/decreases) from baseline (BL) less than (\<) 30 msec, 30 to \<60 msec, more than or equal to (\>=) 60 msec.

Time frame:
Screening, C1D1, C1D21, Day 1 of subsequent cycles, and EOT (maximum reached: C12)
Reported as:
Number · participants
Number of Participants With QTc Values Meeting Categorical Summarization Criteria
participantsPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
QTcB <=450 msec712
QTcB 450 to <=480 msec618
QTcB 480 to <=500 msec211
QTcB >500 msec000
QTcF <=450 msec1326
QTcF 450 to <=480 msec105
QTcF 480 to <=500 msec110
QTcF >500 msec000
QTcB increase from BL <30 msec1136
QTcB increase from BL 30-<60 msec405
QTcB increase from BL >=60 msec000
QTcF increase from BL <30 msec1439
QTcF increase from BL 30-<60 msec102
QTcF increase from BL >=60 msec000
QTcB decrease from BL <30 msec15311
QTcB decrease from BL 30-<60 msec000
QTcB decrease from BL >=60msec000
QTcF decrease from BL <30 msec1338
QTcF decrease from BL 30-<60 msec203
QTcF decrease from BL >=60 msec000
SecondaryPercentage Change From Baseline in Notch 1 to 4 Ribonucleic Acid (RNA) in Blood

As PF-03084014 acts on the Notch pathway as an inhibitor, it is of interest to investigate its effects, if any, on the Notch family of receptors, mainly Notch 1-4.

Time frame:
C1D1, C1D2, C1D8, C1D21 and EOT (maximum reached: C12)
Reported as:
Mean · percentage change
Percentage Change From Baseline in Notch 1 to 4 Ribonucleic Acid (RNA) in Blood
percentage changePF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Notch 1 RNA, C1D14.240 ± 0.51643.990 ± 0.45814.431 ± 1.1781
Notch 1 RNA, C1D2-5.797 ± 11.0169-7.358 ± 14.6569-10.647 ± 19.1488
Notch 1 RNA, C1D832.557 ± 22.034260.199 ± NA35.305 ± 19.4523
Notch 1 RNA, C1D216.118 ± 17.038217.047 ± 15.670511.214 ± 7.9496
Notch 1 RNA, EOT5.653 ± 12.072218.066 ± 9.41534.177 ± 14.6678
Notch 2 RNA, C1D14.139 ± 0.43443.856 ± 0.88694.351 ± 0.7672
Notch 2 RNA, C1D2-12.830 ± 8.1864-9.617 ± 16.7632-15.441 ± 20.3566
Notch 2 RNA, C1D815.426 ± 22.087643.069 ± NA17.234 ± 18.0896
Notch 2 RNA, C1D212.161 ± 9.74349.756 ± 22.63304.985 ± 7.6829
Notch 2 RNA, EOT-1.250 ± 11.62239.478 ± 28.0500-1.558 ± 10.9137
Notch 3 RNA, C1D114.250 ± NA14.673 ± NA14.765 ± 1.3469
Notch 3 RNA, C1D2—0.311 ± NA-1.186 ± 2.9388
Notch 3 RNA, C1D8-2.532 ± NA4.608 ± NA-0.154 ± 11.1968
Notch 3 RNA, C1D21—1.362 ± NA-11.274 ± 19.4623
Notch 4 RNA, C1D113.903 ± 0.557513.228 ± NA14.309 ± 1.3340
Notch 4 RNA, C1D2—12.215 ± NA2.484 ± 5.9621
Notch 4 RNA, C1D8-13.264 ± 3.5374—-9.427 ± 9.8077
Notch 4 RNA, C1D210.927 ± NA5.616 ± NA-0.500 ± 6.4382
Notch 4 RNA, EOT-3.634 ± 9.062911.821 ± NA-9.975 ± 9.8833

Adverse events

Collected over Baseline up to 28-35 days after treatment discontinuation (up to Day 280). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-03084014 100 mg BID + Docetaxel 75 mg/m^2—4/15 (26.7%)15/15 (100%)
PF-03084014 100 mg BID + Docetaxel 100 mg/m^2—3/3 (100%)3/3 (100%)
PF-03084014 150 mg BID + Docetaxel 75 mg/m^2—6/11 (54.5%)11/11 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders3/151/33/11
LeukopeniaBlood and lymphatic system disorders0/151/30/11
NeutropeniaBlood and lymphatic system disorders0/151/30/11
DiarrhoeaGastrointestinal disorders1/151/30/11
VomitingGastrointestinal disorders0/151/30/11
MastitisInfections and infestations0/151/30/11
PneumoniaInfections and infestations0/151/32/11
Intestinal obstructionGastrointestinal disorders0/150/31/11
SepsisInfections and infestations0/150/31/11
Septic shockInfections and infestations0/150/31/11
Most frequent other events
Showing 10 of 163
Most frequent other events
EventPF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2
NeutropeniaBlood and lymphatic system disorders12/153/38/11
NauseaGastrointestinal disorders11/153/38/11
FatigueGeneral disorders12/152/311/11
PyrexiaGeneral disorders4/153/34/11
RashSkin and subcutaneous tissue disorders3/153/36/11
VomitingGastrointestinal disorders5/151/39/11
DiarrhoeaGastrointestinal disorders10/152/38/11
AnaemiaBlood and lymphatic system disorders10/151/35/11
LeukopeniaBlood and lymphatic system disorders10/152/35/11
ThrombocytopeniaBlood and lymphatic system disorders4/152/32/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)PF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2Total
Mean53.3 ± 13.943.3 ± 17.946.2 ± 12.649.6 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)PF-03084014 100 mg BID + Docetaxel 75 mg/m^2PF-03084014 100 mg BID + Docetaxel 100 mg/m^2PF-03084014 150 mg BID + Docetaxel 75 mg/m^2Total
Female1531129
Male0000
08

Study locations

16 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, IDS Pharmacy
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Stanford Hospital & Clinics-DRUG SHIPMENT ADDRESS only
    Stanford, California 94305, United States
  • Stanford Hospital & Clinics
    Stanford, California 94305, United States
  • Stanford Women's Cancer Center
    Stanford, California 94305, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Karmanos Cancer Institute (KCI)
    Detroit, Michigan 48201, United States
  • UNC Cancer Hospital Infusion Pharmacy
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals, The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7600, United States
  • Jules Bordet Institut
    Bruxelles, 1000, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Instituto Europeo di Oncologia
    Milano, 20141, Italy
  • Instituto Catalan de Oncologia de L'Hospitalet de Llobregat(ICO)
    Barcelona, 08908, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Dec 2015, 25 months.

Results were first posted in Mar 2019, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2013
First posted
Jun 12, 2013
StartActual
Nov 4, 2013
Primary completionActual
Dec 24, 2015
CompletionActual
Dec 24, 2015
Results first posted
Mar 15, 2019
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01876251
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 12, 2013
Start date
Nov 4, 2013
Primary completion
Dec 24, 2015
Completion
Dec 24, 2015
Results posted
Mar 15, 2019
Last update
Mar 15, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion